LENZ Therapeutics, Inc. (LENZ) News
Follow LENZ Therapeutics, Inc. (LENZ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G/A LENZ Therapeutics, Inc. Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:21 PM UTC
M
LENZ Therapeutics Reports 2026 Revenue of $3.38 Million
Revenue fell 72.9% from $12.5 million a year earlier. Net loss widened to $30.97 million from $16.7 million, while diluted loss per share was $0.99 versus $0.59.
EARNINGS | Nov 03, 2026, 09:12 PM UTC
M
LENZ Therapeutics Reports Quarterly Results for Quarter Ended September 30
LENZ Therapeutics reported results for the quarter ended September 30.
EQUITY | Oct 29, 2026, 12:06 PM UTC
L
Lenz Therapeutics Reports 110,000 VIZZ Prescriptions Since Launch
Lenz Therapeutics reported 50% alongside the 110,000 prescriptions figure.
EQUITY | Oct 28, 2026, 11:18 PM UTC
M
LENZ Therapeutics Reports Q3 2026 Results, Reorganization and CEO Succession
VIZZ sales rose 50% quarter over quarter. The company is prioritizing consumer marketing in a strategic reorganization and announced a CEO succession.
EQUITY | Oct 28, 2026, 08:39 PM UTC
M
LENZ Therapeutics Reports Q3 EPS of USD -0.99
EARNINGS | Oct 28, 2026, 08:39 PM UTC
M
Lenz Therapeutics Approves Reorganization With 75% Headcount Cut
A strategic reorganization will reduce headcount by 75% to 40 employees, according to an SEC filing.
EQUITY | Oct 28, 2026, 08:37 PM UTC
M
LENZ Q3'26 Earnings Preview: EPS Estimate at (0.89) USD
LENZ Therapeutics is scheduled to report Q3'26 results on October 29 before the market opens. EPS is anticipated at (0.89) USD.
EQUITY | Oct 28, 2026, 11:05 AM UTC
L
Clsa, Cantor, RBC, Wolfe, JPM cut ratings on several stocks
Multiple brokers issue rating changes: AMC to Hold at CLSA, BETR to Neutral at Cantor, LENZ to Neutral at BofA, MNPR to Neutral at Cantor, OI to Sector Perform at RBC, SYK to Peer Perform at Wolfe, and TROX to Underweigh
EQUITY | Aug 13, 2026, 10:50 AM UTC
L
LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate
LENZ Therapeutics (NASDAQ: LENZ ) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.06) by 3.77 percent. This is a 92.45 percent decrease over losses of $(0.53) per share fro
EARNINGS | Aug 11, 2026, 08:12 PM UTC
L
LENZ - LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ - LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
EARNINGS | Aug 11, 2026, 08:07 PM UTC
L
LENZ - LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026 - Click For Rele
LENZ - LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
EARNINGS | Aug 04, 2026, 08:05 PM UTC
L
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopi
VIZZ is now available for those who qualify through a convenient telehealth platform in
EQUITY | Jul 06, 2026, 12:15 PM UTC
M
LENZ Expands Eye Drug Reach
LENZ Therapeutics announces an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its eye drop therapy in Australia and New Zealand
EQUITY | Jun 24, 2026, 05:41 PM UTC
M
LENZ Licenses VIZZ
LENZ Therapeutics and Arrotex Pharmaceuticals announce exclusive license and commercialization agreement for VIZZ in Australia and New Zealand
EQUITY | Jun 24, 2026, 12:30 PM UTC